1. Home
  2. ALLO vs DH Comparison

ALLO vs DH Comparison

Compare ALLO & DH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • DH
  • Stock Information
  • Founded
  • ALLO 2017
  • DH 2011
  • Country
  • ALLO United States
  • DH United States
  • Employees
  • ALLO N/A
  • DH N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • DH Computer Software: Prepackaged Software
  • Sector
  • ALLO Health Care
  • DH Technology
  • Exchange
  • ALLO Nasdaq
  • DH Nasdaq
  • Market Cap
  • ALLO 252.9M
  • DH 283.1M
  • IPO Year
  • ALLO 2018
  • DH 2021
  • Fundamental
  • Price
  • ALLO $1.27
  • DH $2.61
  • Analyst Decision
  • ALLO Buy
  • DH Hold
  • Analyst Count
  • ALLO 11
  • DH 6
  • Target Price
  • ALLO $8.67
  • DH $4.28
  • AVG Volume (30 Days)
  • ALLO 2.3M
  • DH 246.1K
  • Earning Date
  • ALLO 11-06-2025
  • DH 11-06-2025
  • Dividend Yield
  • ALLO N/A
  • DH N/A
  • EPS Growth
  • ALLO N/A
  • DH N/A
  • EPS
  • ALLO N/A
  • DH N/A
  • Revenue
  • ALLO N/A
  • DH $242,275,000.00
  • Revenue This Year
  • ALLO N/A
  • DH N/A
  • Revenue Next Year
  • ALLO $100.00
  • DH $0.68
  • P/E Ratio
  • ALLO N/A
  • DH N/A
  • Revenue Growth
  • ALLO N/A
  • DH N/A
  • 52 Week Low
  • ALLO $0.86
  • DH $2.15
  • 52 Week High
  • ALLO $3.78
  • DH $5.68
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 53.43
  • DH 36.55
  • Support Level
  • ALLO $1.16
  • DH $2.60
  • Resistance Level
  • ALLO $1.28
  • DH $2.92
  • Average True Range (ATR)
  • ALLO 0.09
  • DH 0.16
  • MACD
  • ALLO 0.01
  • DH 0.01
  • Stochastic Oscillator
  • ALLO 70.68
  • DH 21.88

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

Share on Social Networks: